Physicochemical Properties
| Molecular Formula | C22H33N3O4 |
| Molecular Weight | 403.523 |
| Exact Mass | 403.247 |
| Elemental Analysis | C, 65.48; H, 8.24; N, 10.41; O, 15.86 |
| CAS # | 1018673-42-1 |
| Related CAS # | 1018673-42-1 |
| PubChem CID | 53630042 |
| Appearance | Light yellow to khaki solid powder |
| Density | 1.2±0.1 g/cm3 |
| Index of Refraction | 1.566 |
| LogP | 2.55 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 10 |
| Heavy Atom Count | 29 |
| Complexity | 518 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | O(C([C@]([H])(C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])N([H])C([H])([H])C1=C([H])N=C(C([H])([H])C([H])([H])C(N([H])O[H])=O)C([H])=C1[H])=O)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] |
| InChi Key | AFDPFLDWOXXHQM-NRFANRHFSA-N |
| InChi Code | InChI=1S/C22H33N3O4/c26-20(25-28)13-12-18-11-10-16(14-23-18)15-24-21(17-6-2-1-3-7-17)22(27)29-19-8-4-5-9-19/h10-11,14,17,19,21,24,28H,1-9,12-13,15H2,(H,25,26)/t21-/m0/s1 |
| Chemical Name | cyclopentyl (2S)-2-cyclohexyl-2-[[6-[3-(hydroxyamino)-3-oxopropyl]pyridin-3-yl]methylamino]acetate |
| Synonyms | GSK3117391; GSK 3117391; GSK-3117391; GSK-3117391A; GSK3117391A; GSK 3117391A; HDAC-IN-3; HDAC-IN 3; HDAC-IN3 |
| HS Tariff Code | 2934.99.03.00 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | HDAC |
| References |
[1]. Preparation of amino acid-based hydroxamic acids as histone deacetylase (HDAC) inhibitors. From PCT Int. Appl. (2008), WO 2008040934 A1 20080410. |
| Additional Infomation | GSK-3117391 is under investigation in clinical trial NCT02965599 (Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis). |
Solubility Data
| Solubility (In Vitro) |
DMSO: 50~81 mg/mL (123.9~200.7 mM) Ethanol: ~15 mg/mL |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4782 mL | 12.3910 mL | 24.7819 mL | |
| 5 mM | 0.4956 mL | 2.4782 mL | 4.9564 mL | |
| 10 mM | 0.2478 mL | 1.2391 mL | 2.4782 mL |